The choice of coronary revascularization method depending on comorbid pathology
https://doi.org/10.21886/2712-8156-2023-4-4-14-21
Abstract
Coronary heart disease plays a leading role in global mortality statistics. Despite the obvious progress in the development of new drug regimens, surgical treatment remains an important component. The high prevalence and complexity of treatment of patients with CHD and comorbid pathology, especially diabetes mellitus and chronic kidney disease, make researchers think about proper approaches to therapy of such patients. The decision to perform revascularization is made in consultation with all Heart Team members, taking into account the results of the invasive study, the presence of complaints in the patient and his "response" to drug therapy. Percutaneous coronary interventions (PCI) are still statistically more likely to result in restenosis and repeat revascularizations than open surgery. Hybrid myocardial revascularization is an alternative method combining the advantages of coronary artery bypass and PCI and reducing the risks of both procedures adverse complications. The choice of the optimal strategy of surgical treatment in patients with comorbid pathology requires special attention.
About the Authors
A. V. Bazilevich
Rostov State Medical University
Russian Federation
Russian Federation
Anna V. Bazilevich – Assistant of surgery department №2, cardiovascular surgeon of cardiosurgery department, Rostov State Medical University.
Rostov-on-Don
R. V. Sidorov
Rostov State Medical University
Russian Federation
Russian Federation
Roman V. Sidorov – Dr. Sci. (Med.)., assistant professor, Professor of surgery department №2, Chief of Cardiology and Cardiovascular surgery Center, Rostov State Medical University.
Rostov-on-Don
M. A. Kaplunovskaya
Rostov State Medical University
Russian Federation
Russian Federation
Milena A. Kaplunovskaya – Student, Rostov State Medical University.
Rostov-on-Don
L. A. Haisheva
Rostov State Medical University
Russian Federation
Russian Federation
Larisa A. Haisheva - Dr. Sci. (Med.), professor of Internal Disease department №4, Rostov State Medical University.
Rostov-on-Don
S. V. Shlyk
Rostov State Medical University
Russian Federation
Russian Federation
Sergey V. Shlyk - Dr. Sci. (Med.), professor, Rector, Rostov State Medical University.
Rostov-on-Don
References
1. Российское кардиологическое общество. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. DOI: 10.15829/1560-4071-2020-4076
2. Рекомендации ESC/EACTS по реваскуляризации миокарда 2018. Российский кардиологический журнал. 2019;(8):151-226. DOI: 10.15829/1560-4071-2019-8-151-226
3. Buddeke J, Bots ML, van Dis I, Visseren FL, Hollander M, Schellevis FG, et al. Comorbidity in patients with cardiovascular disease in primary care: a cohort study with routine healthcare data. Br J Gen Pract. 2019;69(683):e398-e406. DOI: 10.3399/bjgp19X702725
4. Kendir C, van den Akker M, Vos R, Metsemakers J. Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands. Eur J Gen Pract. 2018;24(1):45-50. DOI: 10.1080/13814788.2017.1398318
5. Барбараш О.Л., Семенов В.Ю., Самородская И.В., Евсеева М.В., Рожков Н.А., Сумин А.Н., и др. Коморбидная патология у больных ишемической болезнью сердца при коронарном шунтировании: опыт двух кардиохирургических центров. Российский кардиологический журнал. 2017;(3):6-13. DOI: 10.15829/1560-4071-2017-3-6-13
6. Щукина Е.В., Приколота О.А., Багрий В.А., Андрусяк А.Ю., Рыбалко Г.С., Шестерина Ю.Б., и др. Лечение пациентов с хронической ишемической болезнью сердца и сахарным диабетом 2 типа. Архивъ внутренней медицины. 2023;13(2):97-109. DOI: 10.20514/2226-6704-2023-13-2-97-109
7. Bates ER. Antiplatelet Therapy in Patients with Coronary Disease and Type 2 Diabetes. N Engl J Med. 2019;381(14):1373-1375. DOI: 10.1056/NEJMe1910813
8. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. Erratum in: Eur Heart J. 2020;41(45):4317. DOI: 10.1093/eurheartj/ehz486.
9. Mancini GBJ, Boden WE, Brooks MM, Vlachos H, Chaitman BR, Frye R, et al. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials. Atherosclerosis. 2018;277:186-194. DOI: 10.1016/j.atherosclerosis.2018.04.005
10. Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. 2022;145(9):e722-e759. DOI: 10.1161/CIR.0000000000001040
11. Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, et al. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol. 2019;73(6):629-638. DOI: 10.1016/j.jacc.2018.11.001
12. Ржевская О.Н., Моисеева А.Ю., Эсауленко А.Н., Пинчук А.В., Алиджанова Х.Г. Хроническая болезнь почек и инфаркт миокарда. Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь». 2022;11(1):104-118. DOI: 10.23934/2223-9022-2022-11-1-104-118
13. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10-82.
14. Zannad F, Rossignol P. Cardiovascular Outcome Trials in Patients With Advanced Kidney Disease: Time for Action. Circulation. 2017;135(19):1769-1771. DOI: 10.1161/CIRCULATIONAHA.117.027338
15. Bangalore S, Maron DJ, Hochman JS. Management of Coronary Disease in Patients with Advanced Kidney Disease. Reply. N Engl J Med. 2020;383(11):1091-1092. DOI: 10.1056/NEJMc2024023
16. Шевченко Ю.Л., Борщев Г.Г., Ульбашев Д.С., Землянов А.В. Выбор кондуитов в коронарной хирургии. Вестник НМХЦ им. Н.И. Пирогова. 2019;14(1):97-104. Doi: 10.25881/BPNMSC.2019.69.57.019
17. Шевченко Ю.Л., Сусов Р.П. Послеоперационные инфекционно-воспалительные осложнения в кардиоторакальной хирургии. Вестник НМХЦ им. Н.И. Пирогова. 2022;17(1):84-89. DOI: 10.25881/20728255_2022_17_1_84
18. Han P, Yu H, Xie F, Li M, Chen X, Yu X, et al. Effects of early rehabilitation on functional outcomes in patients after coronary artery bypass graft surgery: a randomized controlled trial. J Int Med Res. 2022;50(3):3000605221087031. DOI: 10.1177/03000605221087031
19. Wang R, Serruys PW, Gao C, Hara H, Takahashi K, Ono M, et al. Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. Eur Heart J. 2021;43(1):56-67. DOI: 10.1093/eurheartj/ehab441
20. Анцыгина ЛН, Кордатов ПН. Принципы реабилитации больных ишемической болезнью сердца после хирургической реваскуляризации миокарда. Физическая и реабилитационная медицина, медицинская реабилитация. 2020;2(2):190-199. DOI: 10.36425/rehab34111
21. Зеньков А.А. Анализ качества жизни при различных методах хирургической реваскуляризации миокарда: проспективное рандомизированное исследование MICSREVS. Вестник Витебского государственного медицинского университета. 2018;17(1):68-80.
22. Nolan S, Filion KB, Atallah R, Moss E, Reynier P, Eisenberg MJ. Hybrid Coronary Revascularization vs Complete Coronary Artery Bypass Grafting for Multivessel Coronary Artery Disease: A Systematic Review and Meta-Analysis. J Invasive Cardiol. 2018;30(12):E131-E149. PMID: 30504516.
23. Yu L, Zhu K, Du N, Si Y, Liang J, Shen R, et al. Comparison of hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: a meta-analysis. J Cardiothorac Surg. 2022;17(1):147. DOI: 10.1186/s13019-022-01903-w
24. Xenogiannis I, Zenati M, Bhatt DL, Rao SV, Rodés-Cabau J, Goldman S, et al. Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies. Circulation. 2021;144(9):728-745. DOI: 10.1161/CIRCULATIONAHA.120.052163
25. Ren J, Royse C, Srivastav N, Lu O, Royse A. Long-Term Survival of Multiple Versus Single Arterial Coronary Bypass Grafting in Elderly Patients. J Clin Med. 2023;12(7):2594. DOI: 10.3390/jcm12072594
26. Bonatti J, Wallner S, Crailsheim I, Grabenwöger M, Winkler B. Minimally invasive and robotic coronary artery bypass grafting-a 25-year review. J Thorac Dis. 2021;13(3):1922-1944. DOI: 10.21037/jtd-20-1535
27. Nenna A, Nappi F, Spadaccio C, Greco SM, Pilato M, Stilo F, et al. Hybrid coronary revascularization in multivessel coronary artery disease: a systematic review. Future Cardiol. 2022;18(3):219-234. DOI: 10.2217/fca-2020-0244
28. Van den Eynde J, Sá MP, De Groote S, Amabile A, Sicouri S, Ramlawi B, et al. Hybrid coronary revascularization versus percutaneous coronary intervention: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2021;37:100916. DOI: 10.1016/j.ijcha.2021.100916
29. Moreno PR, Stone GW, Gonzalez-Lengua CA, Puskas JD. The Hybrid Coronary Approach for Optimal Revascularization: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;76(3):321-333. DOI: 10.1016/j.jacc.2020.04.078
30. Purmessur R, Wijesena T, Ali J. Minimal-Access Coronary Revascularization: Past, Present, and Future. J Cardiovasc Dev Dis. 2023;10(8):326. DOI: 10.3390/jcdd10080326
31. Bhat S, Yatsynovich Y, Sharma UC. Coronary revascularization in patients with stable coronary disease and diabetes mellitus. Diab Vasc Dis Res. 2021;18(2):14791641211002469. DOI: 10.1177/14791641211002469
32. Sanetra K, Buszman PP, Jankowska-Sanetra J, Cisowski M, Fil W, Gorycki B, et al. One-stage hybrid coronary revascularization for the treatment of multivessel coronary artery disease- Periprocedural and long-term results from the "HYBRID-COR" feasibility study. Front Cardiovasc Med. 2022;9:1016255. DOI: 10.3389/fcvm.2022.1016255
33. Fuchs-Buder T, Settembre N, Schmartz D. Hybridoperationssaal [Hybrid operating theater]. Anaesthesist. 2018;67(7):480-487. (In German). DOI: 10.1007/s00101-018-0464-z
34. Li D, Guo Y, Gao Y, An X, Liu Y, Gu S, et al. One-Stop Hybrid Coronary Revascularization Versus Off-Pump Coronary Artery Bypass Grafting in Patients With Multivessel Coronary Artery Disease. Front Cardiovasc Med. 2021;8:755797. DOI: 10.3389/fcvm.2021.755797
35. Li D, Gao J, Guo Y, Jia Y, An X, Liu Y, et al. Risk factor analysis of acute kidney injury after one-stop hybrid coronary revascularization. Ann Palliat Med. 2021;10(7):7398-7405. DOI: 10.21037/apm-21-959
36. Wintgen L, Dakkak AR, Shakaki MA, Wisniewski K, Biancari F, Martens S, et al. Acute kidney injury following coronary artery bypass grafting and control angiography: a comprehensive analysis of 221 patients. Heart Vessels. 2021;36(1):1-6. DOI: 10.1007/s00380-020-01655-4
37. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74(14):1823-1838. DOI: 10.1016/j.jacc.2019.08.1017
Supplementary files
Review
For citations:
Bazilevich A.V., Sidorov R.V., Kaplunovskaya M.A., Haisheva L.A., Shlyk S.V. The choice of coronary revascularization method depending on comorbid pathology. South Russian Journal of Therapeutic Practice. 2023;4(4):14-21. (In Russ.) https://doi.org/10.21886/2712-8156-2023-4-4-14-21
Views:
781
Email this article 